12 Oct 17

Cabozantinib blocks VEGF and c-MET signaling in mouse model of pancreatic cancer Dual inhibition of vascular endothelial growth factor and c-MET signaling inhibited tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer, according to a paper published in Cancer Discovery, the newest journal of the American Association for Cancer Study. ‘Inhibition of VEGF signaling plus c-MET signaling results in a synergistic effect on tumors leading to slowing of tumor growth and decreased invasiveness and metastasis,’ stated business lead researcher Donald M. McDonald, M http://levitrasuomi.org .D., Ph.D., a professor at the University of California San Francisco Comprehensive Cancer Center.


announced today that it has resubmitted its New Drug Program to the U.S. The NDA for OFIRMEV was resubmitted on May 4, 2010. The FDA will determine the kind of resubmission and resulting review timeline subsequent to this NDA submission. On February 10, 2010, Cadence received a Complete Response letter from the FDA which just indicated that the OFIRMEV NDA cannot be approved because of deficiencies observed during the FDA’s facility inspection of Cadence’s third party manufacturer. Cadence met with the FDA on April 16, 2010 to go over the deficiencies outlined in the letter, at which time the company didn’t request any new protection, efficacy, or stability studies. Based upon Cadence’s discussions with the FDA, Cadence offers resubmitted the NDA to move toward potential authorization of OFIRMEV now..